Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy
I. Assess the efficacy of 3,4-diaminopyridine in patients with stable chronic demyelinating polyneuropathy.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
|Study Design:||Allocation: Randomized
Primary Purpose: Treatment
|Study Start Date:||August 1996|
|Estimated Study Completion Date:||August 1996|
PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are randomly assigned to oral 3,4-diaminopyridine (3,4-DAP) or placebo administered for 4 days. After a washout of at least 5 days, patients cross to the alternate therapy for 4 days.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004939
|Study Chair:||Anthony J. Windebank||Mayo Clinic|